虞美霞,王兵,王勇强,高红梅. 血必净对严重脓毒症血小板减少症患者的疗效观察[J]. 中国急救医学, 2017, 37(12): 1087-1090.
Yu Mei-xia, Wang Bing, Wang Yong-qiang, Gao Hong-mei. Clinical efficacy of Xuebijing injection in septic patients with thrombocytopenia. Chinese Journal of Critical Care Medicine, 2017, 37(12): 1087-1090.
[1]Vandijck DM, Blot SI, De Waele JJ, et al. Thrombocytopenia and outcome in critic-ally ill patients with bloodstream infection[J]. Heart Lung, 2010, 39(1):21-26.
[2]Warkentin TE, Aird WC, Rand JH. Platelet, Endothelial Interactions:sepsis, HIT, and Antiphospholipid Syndrome[J]. Hematology, 2003: 497-519.
[3]耿平,夏仲芳,顾健,等. 血必净注射液对严重脓毒症患者早期高凝状态的干预作用[J]. 中国中西医结合急救杂志, 2008, 15(6):346-348.
[4]Dellinger RP, Levy MM, Rhodes A, et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012 [J]. Intensive Care Med, 2012, 39(2):165-228.
[5]Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock [J]. N Engl J Med, 2001, 345(19):1368-1377.
[6]Angus DC, van der Poll T. Severe sepsis and septic shock [J]. N Engl J Med, 2013, 369(21):840-851.
[7]Haznedaroglu IC, Atalar E, Ozturk MA, et al. Throm bopoietin inside the pulmonary vessels inpatients with and without pulmonaty hypertension [J]. Platelets, 2002, 13(7):395-399.
[8]Warkentin TE, Aird WC, Rand JH. Platelet-endothelial Interactions: sepsis, HIT, and antiphospholipid Syndrome[J]. Hematology Am Soc Hematol Edue Program, 2003:497-519.
[9]王兵,王勇强,曹书华,等. 脓毒症患者血小板参数与Toll样受体4表达的关系及中西医结合治疗研究[J]. 中国危重病急救医学, 2011, 23(10):616-620.
[10]McDonald B, Urrutia R, Yipp BG, et al. Intravascular nertrophil extracellular traps capture bacteria from the bloodstream during sepsis [J]. Cell Host Microbe, 2012, 12(3) :324-333.
[11]Vieira-de-Abreu A, Campbell RA, Weyrich AS, et al. Platelets: versatile effector cells in hemostasis, inflammation, and the immune continuum[J]. Semin Immunopathol, 2012, 34(1):5-30.
[12]Sun BW, Chen X. Carbon monoxide releasing molecules: new insights for anticoagulation strategy in sepsis [J]. Cell Mol Life Sci, 2009, 66(3):365-369.
[13]Aukrust P, Damas JK. Solum NO. Soluble CD40 ligand and platelets: self-perpetuating pathogenic loop in thrombosis and inflammation[J]. J Am Coll Cardiol, 2004, 43(12) :2326-2328.
[14]Rahman M, Rller J, Zhang S, et al. Metalloproteinases regulate CD40L shedding from platelets and pulmonary recruitment of neutrophils in abdominal sepsis [J]. Inflamm Res, 2012, 61(6):571-579.
[15]徐俊,杨静,孟令毅,等. 脓毒症患者血清假血友病因子血管性血友病因子裂解酶水平变化的临床意义[J]. 中国急救医学, 2013, 33(5):416-419.
[16]Claus RA, Bockmeyer CL, Sossdorf M, et al. The balance between von-Willebrand factor and its cleaving protease ADAMTS13: biomarker in systemic inflammation and development of organ failure[J]. Curr Mol Med, 2010, 10(2): 236-248.
[17]Westbrook AM, Wei B, Hacke K, et al. The role of tumour necrosis factor-a and tumor necrosis factor receptor signalling in inflammation-associated systemic genotoxieity [J]. Mutagenesis, 2012, 27(1):77-86.
[18]叶小玲,陶珮,陈月娥,等. 槲皮素对脓毒症大鼠肝细胞的保护作用[J]. 中国急救医学, 2015, 35(12): 1075-1078.
[19]Erbas O, Taskiran D. Sepsis-induced changes in behavioral stereotypy in rats: involvement of turnover [J]. J Surg Res, 2014, 186(1):262-268.
[20]曹书华,高红梅,王勇强,等. 肝移植术后多器官功能障碍综合征中西医结合治疗的临床研究[J]. 中国中西医结合急救杂志, 2002, 9(5): 263-266.
[21]赵森伟,柴艳芬.血必净与低分子肝素对严重脓毒症患者凝血功能及预后的影响[J].中华急诊医学杂志, 2011, 20(4): 405-408.
[22]苏媛,董泽华,付培荣,等. 血必净注射液对严重脓毒症患者血小板参数及凝血功能的影响[J]. 中国急救医学, 2011, 31(7):599-601.
[23]赵普宇,蔡明志,张胜利,等. 血必净注射液对发热伴血小板减少综合征的疗效分析[J].中国急救医学, 2014, 34(10): 924-926.